ORGANIC LETTERS

Counterion Induced Translational Isomerism in a Bistable [2]Rotaxane

Bo W. Laursen, Sune Nygaard, Jan O. Jeppesen,* and J. Fraser Stoddart*

Department of Chemistry and Biochemistry, University of California, Los Angeles, 405 Hilgard Avenue, Los Angeles, CA 90095-1569, USA Department of Chemistry, Odense University (University of Southern Denmark), Campusvej 55, DK-5230, Odense M, Denmark

joj@chem.sdu.dk

SUPPORTING INFORMATION

(18 Pages)

Introduction

In this supplement, we describe the experimental procedures for the syntheses of the [2]rotaxanes $1.4PF_6$ and 1.TRISPHAT, together with spectrometric and spectroscopic characterization. We also provide more details on the preparation of Me₄N.TRISPHAT.

Synthesis of the Amphiphilic [2]Rotaxane 1•4PF₆

The [2]rotaxane $1 \cdot 4PF_6$ was synthesized according to the routes outlined sequentially in Schemes S1–S3. Alkylation of BPTTF¹ 2 with 2-[2-(2-iodoethoxy)ethoxy]tetrahydropyran² (3) in DMF gave (Scheme 1) the BPTTF derivative 4 in 67% yield. Removal of the THP-protecting groups with *p*-toluenesulfonic acid (TsOH) gave the diol 5 in 67% yield. The



Scheme S1. Synthesis of the semi-dumbbell compound 11.

monotosylate **6** was obtained in 22% yield by reaction of the diol **5** with one equivalent of *p*-toluenesulfonyl chloride (TsCl). Alkylation of the hydrophobic tetraarylmethane-based stopper³ **7** with **6** in MeCN in the presence of K_2CO_3 gave (70%) the alcohol **8**, which was tosylated using TsCl in CH₂Cl₂ affording **9** in 81% yield. Subsequently, **9** was reacted with the DNP derivative⁴ **10** under alkylation conditions ($K_2CO_3 / \text{LiBr} / \text{MeCN}$) affording the BPTTF derivative **11** in 60% yield, which on treatment with TsOH in THF/EtOH, gave (Scheme 2) the alcohol **12** in 56% yield. The free hydroxyl function in compound **12** was thereafter converted to a tosylate group in 98% yield (**12** \rightarrow **13**) and then to a thiocyanate group in 97% yield (**13** \rightarrow **14**).The thiocyanate group was reduced in situ with NaBH₄, and the resulting thiolate was subsequently coupled with the hydrophilic chloride³ **15** in THF/EtOH to give the



Scheme S2. Synthesis of the dumbbell compound 16.

dumbbell **16** in 68% yield. Finally, the [2]rotaxane **1**•4PF₆ was self-assembled (Scheme 3) under high pressure conditions by using the dumbbell compound **16** as the template for the formation of the encircling CBPQT⁴⁺ tetracation and the [2]rotaxane **1**•4PF₆ was isolated in

47% yield from a mixture of the dumbbell compound **16**, the dicationic precursor⁵ **17**•2PF₆, and the dibromide **18** after they had been subjected to a 10 kbar pressure in DMF at room temperature for 3 days.



Scheme S3. Synthesis of the bistable [2]rotaxane 1•4PF₆.

Experimental Details for the Synthesis of the [2]Rotaxane

General methods: Chemicals were purchased from Aldrich and were used as received, unless indicated otherwise. Bis(pyrrolo[3,4-*d*])tetrathiafulvalene¹ (**2**) (Scheme 1), 2-(2iododethoxy)-ethyl-*p*-toluenesulfonate² (**3**) (Scheme 1), 4-[bis(4-*tert*-butylphenyl)(4ethylphenyl)methyl]-phenol³ (**7**) (Scheme 1), compound⁴ **10** (Scheme 1), the chloride³ **15** (Scheme 2), 1,1''-[1,4-phenylenebis(methylene)]bis(4,4'-bipyridin-1-ium) bis(hexafluorophosphate)⁵ (**17**•2PF₆) (Scheme 3) and morpholinium•TRISPHAT⁶ were all prepared according to literature procedures. Solvents were dried according to literature procedures.⁷ All

reactions were carried out under an anhydrous nitrogen atmosphere. High pressure experiments were carried out in a teflon-tube on a Psika high pressure apparatus. Thin-layer chromatography (TLC) was carried out using aluminium sheets pre-coated with silica gel 60F (Merck 5554). The plates were inspected under UV light and, if required, developed in I₂ vapor. Column chromatography was carried out using silica gel 60F (Merck 9385, 0.040-0.063 mm), which was deactivated by stirring the silica gel in CH_2Cl_2 containing 2% Et₃N for 10 min before it was filtered, washed with CH₂Cl₂ and dried. Melting points were determined on a Büchi melting point apparatus and are uncorrected. ¹H NMR spectra were recorded at room temperature on a Bruker ARX500 spectrometer (500 MHz), Bruker ARX400 spectrometer (400 MHz), or on a Gemini-300BB instrument (300 MHz), using residual solvent as the internal standard. ¹³C NMR spectra were recorded at room temperature on a Gemini-300BB instrument (75 MHz), using residual solvent as the internal standard. ¹⁹F NMR spectra were recorded at room temperature on a Bruker ARX400 spectrometer (376 MHz), while ³¹P NMR spectra were recorded at room temperature on Bruker ARX400 instrument (161 MHz). All chemical shifts are quoted on a δ scale, and all coupling constants (J) are expressed in Hertz (Hz). The following abbreviations are used in listing the NMR spectra: s = singlet, d = doublet, t = triplet, q = quartet, and bs = broad singlet, and m = multiplet. Samples were prepared using CD₃COCD₃ or CD₃SOCD₃ purchased from Cambridge Isotope Labs. Electron impact ionization mass spectrometry (EI-MS) was performed on a Varian MAT 311A instrument and matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) was performed on a Kratos Kompact MALDI-TOF instrument, utilizing a 2,5-dihydroxybenzoic acid matrix, Fourier Transform matrix-assisted laser-desorption/ionisation mass spectrometry (FT-MALDI-MS) was performed on an IonSpec 4.7 tesla Ultima Fourier Transform mass spectrometer, utilizing a 2,5-dihydroxybenzoic acid (DHP) matrix, while electrospray mass spectra (ES-MS) were obtained from a from a Sciex

API III⁺ mass spectrometer. Infrared (IR) spectra were recorded on a Perkin-Elmer 580 spectrophotometer. Microanalyses were performed by the Atlantic Microlab, Inc., Atlanta, Georgia. UV-vis spectra were recorded at room temperature on a Shimadzu UV-160 instrument.

Compound 4. Compound **2** (0.80 g, 2.83 mmol) was dissolved in anhydrous DMF (30 mL), cooled to 0 °C, and degassed (N₂, 10 min) before the iodide **3** (2.50 g, 8.33 mmol) followed by NaH (0.80 g of a 60% suspension in mineral oil, 20.0 mmol) was added to the yellow solution. The reaction mixture was stirred for 3 h at 0 °C, whereupon the reaction mixture was diluted with CH₂Cl₂ (500 mL), washed with brine (10 × 150 mL) and dried (MgSO₄). Removal of the solvent gave a brown oil which was purified by column chromatography (deactivated SiO₂: CH₂Cl₂/MeOH 19:1). The broad yellow band (R_f = 0.6) was collected and concentrated, affording 1.19 g (67%) of the title compound **4** as a yellow oil. Data for **4**: ¹H NMR (CD₃SOCD₃, 300 MHz) δ 1.40–1.80 (m, 12H), 3.40–4.00 (m, 20H), 4.54 (bs, 2H), 6.82 (s, 4H); ¹³C NMR (CD₃SOCD₃, 75 MHz) δ 19.6, 25.6, 30.8, 50.3, 61.7, 66.4, 70.1, 70.7, 98.5, 114.2, 117.2, 119.5; MS(EI) *m*/*z* 626 (M⁺, 24), 542 (18), 458 (10). Anal. Calcd for C₂₈H₃₈N₂O₆S₄: C, 53.65; H, 6.11; N, 4.47. Found: C, 53.78; H, 6.09; N, 4.43.

Compound 5. A solution of compound **4** (1.14 g, 1.82 mmol) in THF–EtOH (50 mL, 1:1 v/v) was degassed (N₂, 10 min) before TsOH•H₂O (~10 mg, cat) was added. The yellow solution was stirred for 20 h at room temperature, whereupon it was diluted with CH₂Cl₂ (100 mL). The combined organic phase was washed with a saturated aqueous NaHCO₃ solution (200 mL), H₂O (300 mL) and dried (MgSO₄). Concentration in vacuo gave a yellow powder, which was subjected to column chromatography (deactivated SiO₂: CH₂Cl₂/MeOH 24:1). The greenish yellow band ($R_f = 0.3$) was collected and the solvent evaporated to give 0.56 g (67%) of the title compound **5** as a yellow powder. Data for **5**: mp 138–139 °C;

¹H NMR (CD₃SOCD₃, 300 MHz) δ 3.39–3.42 (m, 8H), 3.64 (t, J = 5.2 Hz, 4H), 4.00 (t, J = 5.2 Hz, 4H), 4.59 (t, J = 5.2 Hz, 2H), 6.82 (s, 4H); ¹³C NMR (CD₃SOCD₃, 75 MHz) δ 49.8, 60.2, 70.2, 72.2, 113.7, 116.7, 118.9; MS(MALDI–TOF) *m*/*z* 458 (M⁺, 100). Anal. Calcd for C₁₈H₂₂N₂O₄S₄: C, 47.14; H, 4.83; N, 6.11; S, 27.97. Found: C, 47.04; H, 4.83; N, 6.08; S, 27.73.

Compound 6. TsCl (0.57 g, 2.99 mmol) dissolved in anhydrous CH₂Cl₂ (30 mL) was added dropwise over 20-30 min to an ice-cooled solution of the diol 5 (1.30 g, 2.83 mmol), Et_3N (2 mL, 1.5 g, 14 mmol), and DMAP (~10 mg, cat) in anhydrous CH_2Cl_2 (90 mL). The reaction mixture was stirred for 20 h (0 °C to rt), whereupon Al₂O₃ (10 g, Brockmann 1, neutral) was added and the solvent removed. The resulting green powder was directly subjected to column chromatography (deactivated SiO_2) and 0.90 g (41%) of the bistosylate was eluted with CH₂Cl₂, whereupon the eluent was changed to CH₂Cl₂/MeOH (99:1) and the yellow band $(R_{\rm f} = 0.5)$ containing the desired monotosylate was collected and concentrated to give 0.38 g (22%) of the title compound 6 as a yellow solid. Finally, 0.45 g (34%) of the starting material 5 was eluted CH₂Cl₂/MeOH (23:2). Data for 6: ¹H NMR (CD₃SOCD₃, 300 MHz) δ 2.42 (s, 3H), 3.36-3.66 (m, 10H), 3.93-4.11 (m, 6H), 4.59 (t, J = 5.2 Hz, 1H), 6.74 (s, 2H), 6.83 (s, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.0 Hz, 2H); ¹³C NMR (CD₃SOCD₃, 75 MHz) δ 21.1, 49.5, 49.7, 60.2, 67.7, 69.8, 70.1, 70.2, 72.1, 113.6, 113.7, 116.7, 116.8, 118.9, 127.6, 130.1, 132.5, 144.9 (one line is missing/overlapping); MS(MALDI-TOF) m/z 612 (M⁺, 100). Anal. Calcd for C₂₅H₂₈N₂O₆S₅: C, 49.00; H, 4.61; N, 4.57; S, 26.16. Found: C, 48.83; H, 4.66; N, 4.67; S, 25.97.

Compound 8. A solution of the monotosylate **6** (0.37 g, 0.60 mmol) and **7** (0.86 g, 1.80 mmol) in anhydrous MeCN (50 mL) containing K_2CO_3 (0.50 g, 3.6 mmol), LiBr (10 mg,

cat) and 18-crown-6 (~10 mg, cat), was heated at 75 °C for 20 h. After cooling down to room temperature the reaction mixture was filtered and the residue washed thoroughly with MeCN (20 mL). The combined organic phase filtrate was concentrated in vacuo and the yellow residue was purified by column chromatography (deactivated SiO₂: CH₂Cl₂/Me₂CO 97:3). The yellow band ($R_f = 0.2$) was collected and the solvent evaporated to give 0.38 g (70%) of the title compound **8** as a yellow foam. Data for **8**: ¹H NMR (CD₃SOCD₃, 300 MHz) δ 1.17 (t, J = 7.6 Hz, 3H), 1.26 (s, 18H), 2.53 (q, J = 7.6 Hz, 2H), 3.39–3.49 (m, 4H), 3.62–3.71 (m, 6H), 3.99–4.02 (m, 6H), 4.59 (t, J = 5.2 Hz, 1H), 6.80–6.84 (m, 6H), 7.01–7.12 (m, 10H), 7.28–7.31 (m, 4H); MS(EI) *m*/*z* 917 (M⁺, 55), 105 (100). Anal. Calcd for C₅₃H₆₀N₂O₄S₄: C, 69.39; H, 3.05; N, 6.59; S, 13.98. Found: C, 69.63; H, 2.91; N, 6.63; S, 13.73.

Compound 9. A solution of compound **8** (0.38 g, 0.41 mmol), TsCl (0.16 g, 0.82 mmol), Et₃N (0.5 mL, 0.35 g, 3.3 mmol), and DMAP (~10 mg, cat) in anhydrous CH₂Cl₂ (150 mL) was stirred at room temperature for 20 h. Al₂O₃ (10 g, Brockmann 1, neutral) was added, whereupon the solvent was removed and the residue was purified by column chromatography (deactivated SiO₂: CH₂Cl₂/Me₂CO 99:1). The yellow band (R_f = 0.15) was collected and the solvent evaporated to give 0.35 g (81%) of the title compound **9** as a yellow foam. Data for **9**: ¹H NMR (CD₃COCD₃, 300 MHz) δ 1.18 (t, *J* = 7.5 Hz, 3H), 1.29 (s, 18H), 2.43 (s, 3H), 2.60 (q, *J* = 7.5 Hz, 2H), 3.61–3.66 (m, 4H), 3.75–3.79 (m, 4H), 3.98–4.16 (m, 8H), 6.64 (s, 2H), 6.73 (s, 2H), 6.81 (d, *J* = 9.0 Hz, 2H), 7.09–7.15 (m, 10H), 7.28–7.32 (m, 4H), 7.45 (d, *J* = 8.4 Hz, 2H), 7.78 (d, *J* = 8.4 Hz, 2H); MS(FT-MALDI) *m*/z 1093 (M⁺ + Na, 2), 1070 (M⁺, 100), 921 (15). Anal. Calcd for C₆₀H₆₆N₂O₆S₅: C, 67.26; H, 6.21; N, 2.61; S, 14.96. Found: C, 65.78; H, 6.24; N, 2.36; S, 14.91.

Compound 11. A solution of the tosylate **9** (0.64 g, 0.60 mmol) and **10** (0.26 g, 0.79 mmol) in anhydrous MeCN (50 mL) containing K_2CO_3 (0.34 g, 2.4 mmol), LiBr (10 mg,

cat) and 18-crown-6 (~10 mg, cat), was heated under reflux for 2 d. After cooling down to room temperature the reaction mixture was filtered and the residue washed with MeCN (2 × 50 mL). The combined organic phase filtrate was concentrated in vacuo and the yellow oily residue was purified by column chromatography (deactivated SiO₂: CH₂Cl₂/EtOH 97:3). The yellow band was collected and the solvent evaporated affording 0.44 g (60%) of the title compound **11** as a yellow foam. Data for **11**: ¹H NMR (CD₃COCD₃, 300 MHz) δ 1.20 (t, J = 7.6 Hz, 3H), 1.29 (s, 18H), 1.49–1.53 (m, 6H), 2.60 (q, J = 7.6 Hz, 2H), 3.37–3.48 (m, 1H), 3.54–3.64 (m, 1H), 3.75–4.00 (m, 14H), 4.08–4.13 (m, 6H), 4.29–4.32 (m, 4H), 4.63 (bs, 1H), 6.76 (s, 2H), 6.77 (s, 2H), 6.84 (d, J = 8.9 Hz, 2H), 6.94–6.97 (m, 2H), 7.09–7.15 (m, 10H), 7.30–7.44 (m, 6H), 7.80 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H); MS(FT–MALDI) m/z 1269 (M⁺ + K, 10), 1253 (M⁺ + Na, 10), 1230 (M⁺, 100).

Compound 12. A solution of compound **11** (0.40 g, 0.32 mmol) in THF–EtOH (40 mL, 1:1 v/v) was degassed (N₂, 10 min) before TsOH•H₂O (~10 mg, cat) was added. The yellow solution was stirred for 16 h at room temperature, whereupon it was diluted with CH₂Cl₂ (50 mL). The combined organic phase was washed with a saturated aqueous NaHCO₃ solution (50 mL), H₂O (50 mL) and dried (MgSO₄). Concentration in vacuo gave a yellow oil, which was subjected to column chromatography (deactivated SiO₂: CH₂Cl₂/EtOAc 1:1). The yellow band ($R_f = 0.4$) was collected and the solvent evaporated to give 0.21 g (56%) of the title compound **12** as a yellow foam. Data for **12**: ¹H NMR (CD₃COCD₃, 300 MHz) δ 1.24 (t, J = 7.6 Hz, 3H), 1.33 (s, 18H), 2.64 (q, J = 7.6 Hz, 2H), 3.50–3.75 (m, 5H), 3.82–3.86 (m, 4H), 3.91–3.94 (m, 2H), 3.97–4.03 (m, 4H), 4.08–4.19 (m, 6H), 4.32–4.36 (m, 4H), 6.80 (s, 2H), 6.81 (s, 2H), 6.89 (d, J = 8.9 Hz, 2H), 6.99–7.01 (m, 2H), 7.13–7.20 (m, 10H), 7.33–7.48 (m, 6H), 7.83–7.89 (m, 2H); MS(FT–MALDI) m/z 1185 (M⁺ + K, 5), 1169 (M⁺ + Na, 20), 1146 (M⁺, 100). **Compound 13.** A solution of compound **12** (0.20 g, 0.17 mmol), TsCl (0.068 g, 0.35 mmol), Et₃N (0.2 mL, 0.14 g, 1.4 mmol), and DMAP (~10 mg, cat) in anhydrous CH₂Cl₂ (50 mL) was stirred at room temperature for 20 h, whereupon the solvent was removed and the yellow solid was purified by column chromatography (deactivated SiO₂: CH₂Cl₂/EtOAc 19:1). The yellow band ($R_f = 0.6$) was collected and the solvent evaporated to give 0.22 g (98%) of the title compound **13** as a yellow foam. Data for **13**: ¹H NMR (CD₃COCD₃, 300 MHz) δ 1.20 (t, J = 7.5 Hz, 3H), 1.33 (s, 18H), 2.36 (s, 3H), 2.60 (q, J = 7.5 Hz, 2H), 3.77–3.83 (m, 6H), 3.86–3.96 (m, 6H), 4.07–4.15 (m, 6H), 4.20–4.25 (m, 4H), 4.29–4.32 (m, 2H), 6.75 (s, 2H), 6.77 (s, 2H), 6.83 (d, J = 9.0 Hz, 2H), 6.94–6.97 (m, 2H), 7.09–7.15 (m, 10H), 7.30–7.35 (m, 7H), 7.39 (t, J = 8.5 Hz, 1H), 7.77–7.83 (m, 4H); MS(FT–MALDI) m/z 1300 (M⁺, 100).

Compound 14. The tosylate **13** (0.22 g, 0.17 mmol) was dissolved in anhydrous Me₂CO (50 mL) and KSCN (0.49 g, 5.04 mmol) was added in one portion. The yellow reaction mixture was heated under reflux for 1 d, whereupon additional KSCN (0.49 g, 5.04 mmol) was added. The reaction mixture was heated under reflux for further 1 d before being cooled to room temperature. After removal of the solvent, the yellow residue was dissolved in CH₂Cl₂ (100 mL), washed with H₂O (2 × 50 mL) and dried (MgSO₄). Concentration in vacuo gave 0.20 g (97%) of the title compound **14** as a yellow foam. Data for **14**: ¹H NMR (CD₃COCD₃, 500 MHz) δ 1.20 (t, *J* =7.6 Hz, 3H), 1.29 (s, 18H), 2.60 (q, *J* = 7.6 Hz, 2H), 3.37 (t, *J* = 5.7 Hz, 2H), 3.78–3.81 (m, 4H), 3.89 (t, *J* = 4.6 Hz, 2H), 3.93–3.95 (m, 2H), 3.99 (t, *J* = 4.6 Hz, 2H), 4.04–4.08 (m, 2H), 4.09–4.13 (m, 6H), 4.29–4.31 (m, 2H), 4.33–4.35 (m, 2H), 6.76 (s, 2H), 6.77 (s, 2H), 6.84 (d, *J* = 8.8 Hz, 2H), 6.95–6.98 (m, 2H), 7.10–7.15 (m, 10H), 7.30–7.32 (m, 4H), 7.37 (t, *J* = 8.5 Hz, 1H), 7.42 (t, *J* = 8.5 Hz, 1H), 7.81 (d, *J* = 8.5 Hz, 1H), 7.85 (d, *J* = 8.5 Hz, 1H); MS(FT–MALDI) *m*/z 1226 (M⁺ + K, 15), 1210 (M⁺ + Na, 15), 1187 (M⁺, 100): IR (KBr) ν 2154 (S-C=N) cm⁻¹.

Dumbbell 16. Compound **14** (0.19 g, 0.16 mmol) and the chloride **15** (0.14 g, 0.18 mmol) were dissolved in anhydrous THF/EtOH (2:1 v/v, 50 mL), after which powdered NaBH₄ (0.060 g, 1.6 mmol) was added in one portion. The reaction mixture was stirred for 1 d at room temperature whereupon additional NaBH₄ (0.060 g, 1.6 mmol) was added and the reaction mixture was stirred for further 3 d at room temperature. Thereafter, it was poured into an ice cooled saturated aqueous NH₄Cl solution (50 mL) and extracted with CH₂Cl₂ (2×50 mL). The combined organic extracts were dried ($MgSO_4$) and concentration in vacuo gave a yellow oil, which was purified by column chromatography (deactivated SiO₂: CH₂Cl₂/EtOAc 3:2). The yellow band ($R_f = 0.4$) was collected and the solvent evaporated affording 0.21 g (68%) of the title compound 16 as a yellow foam Data for 16: ¹H NMR (CD₃COCD₃, 500 MHz) δ 1.20 (t, J = 7.6 Hz, 3H), 1.29 (s, 18H), 2.60 (m, 4H), 3.29 (s, 9H), 3.48–3.50 (m, 6H), 3.62–3.64 (m, 6H), 3.75–3.82 (m, 14H), 3.84–3.86 (m, 2H), 3.92–3.94 (m, 4H), 4.07–4.12 (m, 12H), 4.24– 4.27 (m, 2H), 4.30–4.32 (m, 2H), 4.87 (s, 2H), 4.96 (s, 4H), 6.74 (s, 2H), 6.74 (s, 2H), 6.75 (s, 2H), 6.80–6.98 (m, 10H), 7.10–7.15 (m, 10H), 7.28–7.41 (m, 12H), 7.79 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 8.6 Hz, 1H); MS(MALDI-TOF) m/z 1925 (M⁺, 100). Anal. Calcd for C₁₁₀H₁₂₈N₂O₁₈S₅: C, 68.58; H, 6.70; N, 1.45. Found: C, 68.41; H, 6.75; N, 1.29.

[2]Rotaxane 1•4PF₆. A solution of the dumbbell 16 (0.20 g, 0.10 mmol), 17•2PF₆ (0.22 g, 0.31 mmol), and the dibromide 18 (0.082 g, 0.31 mmol) in anhydrous DMF (8 mL) was transferred to a teflon-tube and subjected to 10 kbar of pressure at room temperature for 3 d. The greenish brown solution was directly subjected to column chromatography (deactivated SiO₂) and unreacted dumbbell was eluted with Me₂CO, whereupon the eluent was changed to Me₂CO/NH₄PF₆ (1.0 g NH₄PF₆ in 100 mL Me₂CO) and the greenish brown band was collected. Most of the solvent was removed in vacuo ($T < 30^{\circ}$ C), followed by addition of H₂O (100 mL). The resulting precipitate was collected by filtration, washed with H₂O (2 × 20 mL)

and Et₂O (2 × 30 mL) and dried in vacuo over P₂O₅, affording 0.15 g (47%) of the title compound **1**•4PF₆ as a brown solid. Data for **1**•4PF₆. The data given below are for the 1:1 mixture of the two translational isomers; ¹⁹F NMR (CD₃COCD₃, 376 MHz) δ –72.4 (d); ³¹P NMR (CD₃COCD₃, 161 MHz) δ –144.2 (septet); MS(ES) *m*/*z* 1369 ([M – 2PF₆]²⁺, 15), 864 ([M – 3PF₆]³⁺, 80), 612 ([M – 4PF₆]⁴⁺, 100). Anal. Calcd for C₁₄₆H₁₆₀F₂₄N₆O₁₈P₄S₅•2H₂O: C, 57.25; H, 5.40; N, 2.74; S, 5.23. Found: C, 57.05; H, 5.20; N, 2.82; S, 5.04.

[2]Rotaxane 1•4TRISPHAT. Me₂CO solutions of 1•4PF₆ (0.025 g, 0.0083 mmol) and morpholinium•TRISPHAT (0.035 g, 0.041 mmol) were mixed at room temperature and the solvent removed. The resulting solid material was redissolved in CHCl₃ (125 mL) and washed with milli-Q H₂O (80 mL). The two phases were separated and the aqueous phase extracted with CHCl₃ (2 × 30 mL). The combined organic phases were washed with milli-Q H₂O (2 × 50 mL) and dried (MgSO₄). Removal of the solvent gave a green solid wherefrom excess morpholinium•TRISPHAT (identified from the morpholinium signals in the ¹H NMR spectrum) was removed by reprecipitating the product from Me₂CO/Et₂O twice, providing 0.033 g (72%) of the title compound 1•4TRISPHAT as a green solid. Data for 1•4TRISPHAT: ³¹P NMR (CD₃COCD₃, 161 MHz) δ –80.7 (s); MS(ES) *m*/*z* 1992 ([M – TRISPHAT]²⁺, 13), 1072 ([M – TRISPHAT³⁺, 100), 612 ([M – 4TRISPHAT]⁴⁺, 12).

Me₄N•TRISPHAT. A solution of morpholinium•TRISPHAT (0.050 mg, 0.058 mmol) in CH₂Cl₂ (150 mL) was washed with an aqueous solution containing a large excess of Me₄N•Br followed by washing with H₂O. The two phases were separated and the organic phase dried (MgSO₄) before the solvent was removed, providing 0.045 g (0.053 mmol) of the title compound Me₄N•TRISPHAT as a white solid. Data for Me₄N•TRISPHAT: ¹H NMR (CD₃COCD₃, 400 MHz) δ 3.44 (s, 12H); ³¹P NMR (CD₃COCD₃, 161 MHz) δ -80.7 (s).

Spectroscopic Characterization of 1•4PF₆ and 1•4TRISPHAT

A comparison of the full ¹H NMR spectra (400 MHz) of $1 \cdot 4PF_6$ and $1 \cdot 4TRISPHAT$ recorded in CD₃COCD₃ is shown in Figure S1.



Figure S1. ¹H NMR spectra (400 MHz) of **1**•4PF₆ (black trace) and **1**•4TRISPHAT (blue trace) recorded in CD₃COCD₃ at 295 K.

Figure S2 show a comparsion of the ¹⁹F NMR spectra (376 MHz) of $1 \cdot 4PF_6$ and $1 \cdot 4TRISPHAT$ recorded in CD₃COCD₃, while Figure S3 show a comparsion of the ³¹P NMR spectra (161 MHz) of $1 \cdot 4PF_6$ and $1 \cdot 4TRISPHAT$ recorded in CD₃COCD₃.



Figure S2. ¹⁹F NMR spectra (376 MHz) of **1**•4PF₆ (black line) and **1**•4TRISPHAT (blue line) recorded in CD₃COCD₃ at 295 K.



Figure S3. ³¹P NMR spectra (161 MHz) of **1**•4PF₆ (black trace) and the product of the anion exchange **1**•4TRISPHAT (blue trace) recorded in CD₃COCD₃ at 295 K.

Spectrometric Characterization of 1•4PF₆ and 1•4TRISPHAT

Electrospray mass spectra (ES-MS) recorded of $1 \cdot 4PF_6$ and $1 \cdot 4TRISPHAT$ are depicted in Figure S4 and S5, respectively.



Figure S4. ES-MS spectrum (Me₂CO) of $1 \cdot 4PF_6$ together with a table comparing the location of the actual peaks with the calculated peaks.



Figure S5. ES-MS spectrum (Me₂CO) of **1**•TRISPHAT together with a table comparing the location of the actual peaks with the calculated peaks.

Titration of 1•4TRISPHAT with Bu₄N•PF₆

The titration was carried out by adding $Bu_4N \cdot PF_6$ to a Me₂CO solution of 1•4TRISPHAT and monitoring the growth/decrease of the charger transfer absorption bands at 540 and 825 nm. Figure S6 illustrates the UV-vis spectra recorded by adding $Bu_4N \cdot PF_6$ to a Me₂CO solution of 1•4TRISPHAT.



Figure S6. UV-vis spectra recorded of 1•4TRISPHAT in Me₂CO at 295 K upon addition of increasing amounts of Bu₄N•PF6. The arrows show the evolution of the charge transfer bands of 1•4TRISPHAT as Bu₄N•PF₆ is added. The green trace show the spectrum of the pure 1•4TRISPHAT solution, while the red trace is after addition of three equivalents of Bu₄N•PF₆.

References

- Jeppesen, J. O.; Takimiya, K.; Jensen, F.; Brimert, T.; Nielsen, K.; Thorup, N.; Becher J. J. Org. Chem. 2000, 65, 5794–5805.
- (2) Hansen, J. G.; Bang, K. S.; Thorup, N.; Becher, J. Eur. J. Org. Chem. 2000, 2135–2144.
- (3) Collier, C. P.; Jeppesen, J. O.; Luo, Y.; Perkins, J.; Wong, E. W.; Heath, J. R.; Stoddart, J. F. J. Am. Chem. Soc. 2001, 123, 12632–12641.
- (4) Yamamoto, T.; Tseng, H.-R.; Stoddart, J. F.; Balzani, V.; Credi, A.; Marchioni, F.;
 Venturi, M. Collect. Czech. Chem. C. 2003, 68, 1488–1514.
- (5) Anelli, P.-L.; Ashton, P. R.; Ballardini, R.; Balzani, V.; Gandolfi, M. T.; Goodnow, T. T.; Kaifer, A. E.; Philp, D.; Pietraszkiewicz, M.; Prodi, L.; Reddington, M. V.; Slawin, A. M. Z.; Spencer, N.; Vicent, C.; Williams, D. J. J. Am. Chem. Soc. 1992, 114, 193–218.
- (6) Lacour, J.; Ginglinger, C.; Grivet, C.; Bernardinelli, G. Angew. Chem. Int. Ed. Engl. 1997, 36, 608–610.
- D. D. Perrin, W. L. F. Armarego, *Purification of Laboratory Chemicals*, Pergamon Press, New York, **1988**.